Recent research highlights the importance of conducting clinical trials in more locations, showing that to truly improve diversity, regulators and sponsors must move beyond traditional tactics like modifying trial enrollment criteria or convincing underrepresented populations of the value of clinical research.
Clinical Trial Diversity: Data Points to Structural, Not Patient-Specific Solutions
Minorities are more likely to participate in cancer clinical trials than white people, but they are less likely to get the chance to say yes, highlighting the importance of bringing studies to different locations if sponsors are to be successful at increasing diversity.
More from Clinical Trials
More from R&D
• By
The European Medicines Agency’s qualification of the AIM-NASH tool is said to signify a major advancement for clinical trials for metabolic dysfunction-associated steatohepatitis. The market size for MASH treatments is expected to grow substantially in the coming years.
• By
As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.
• By
Experts working in the advanced therapy space say the US has less strict criteria for regulatory pathways for cell and gene therapies than the EU, particularly for products in early development.